Navidea's Lymphoseek shows positive meta-analysis results Navidea announced results from a meta-analysis study of Lymphoseek (technetium Tc 99m tilmanocept) Injection, a novel, receptor-targeted, small-molecule radiopharmaceutical. The study compared Lymphoseek performance data from a pre-planned interim analysis of its Phase 3 clinical trial versus published data from the ACOSOG Z-0360 trial which was done using radiolabeled sulfur colloid. Results demonstrated that Lymphoseek identified sentinel lymph nodes in subjects with squamous cell carcinoma of the head or neck with a False Negative Rate of 2.56%, whereas sulfur colloid demonstrated an FNR of 10%. Lymphoseek identified SLNs with an overall accuracy of 99%, versus an overall accuracy of sulfur colloid of 97%.
Subscribe for More Information